$85.92
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Overview
52-week range
$13
$155
51% of range
Avg surprise (last 3)
+12.0%
Avg reaction (last 2)
-2.7%
0% positive
Latest IV / EM
92%
EM ±21.1% · $85 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-2.15 | $-2.37 | +9.3% | +23.2% | -1.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-2.28 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-1.85 | $-2.92 | +36.6% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-2.80 | $-2.55 | -9.8% | — | -3.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.84 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $125.48 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.77 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-4.39 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-4.31 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$2.50 | -$1.85 | -35.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1M | $0 | — | $0 | $100,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-31M | — | $-34M | $-27M | $-43M | — | $-47M | $-161M |
| Net income | $-33M | — | $-35M | $-29M | $-43M | — | $-44M | $1.86B |
| EPS (diluted) | $-2.15 | — | $-2.28 | $-1.85 | $-2.80 | — | $-2.84 | $125.48 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $162M | $124M | $153M | $187M | $217M | $153M | $196M | $227M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $171M | $133M | $161M | $194M | $223M | $160M | $207M | $242M |
| Total assets | $184M | $146M | $177M | $212M | $243M | $181M | $223M | $258M |
| Long-term debt | $175M | $101M | $100M | $99M | $99M | $0 | $0 | $0 |
| Total liabilities | $205M | $138M | $141M | $144M | $148M | $47M | $44M | $39M |
| Total equity | $-21M | $8M | $37M | $69M | $94M | $134M | $178M | $219M |